Abbott (Large Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Abbott India Limited |
|||
|
Price: ₹28,655.35 | ||
| 52 Week Low: ₹22,000.00 52 Week High: ₹30,521.00 |
|||
| Market Capital: 57,849.83 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - General | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Abbott Share Price Target For 2024
- 1.1.1: Abbott Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Abbott Share Price Target For 2025
- 1.2.1: Abbott Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Abbott Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Abbott Brief Company Overview
- 4: Abbott Financial Performance
- 4.0.1: Is Abbott A Good Buy For Long Term?
To predict the Abbott's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Abbott Share Price Target For 2024
The line chart displays the monthly closing prices of Abbott with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Abbott shares in 2024, see the table below.
Abbott Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 29525.0 (+3.03%) | Price Action: Oct 2024 High |
| 2024 Target 2 | 29215.4 (+1.95%) | Price Action: 31 Oct 2024 High |
| 2024 Target 1 | 28888.05 (+0.81%) | Price Action: 09 Dec 2024 Low |
| Current Price | 28655.35 | Abbott's share price as of 20 Dec 2024 |
| Stop Loss 1 | 28550.0 (-0.37%) | Fibonacci Retracement Level 50.00% |
| Stop Loss 2 | 28259.65 (-1.39%) | Price Action: 31 Oct 2024 Low |
| Stop Loss 3 | 27970.0 (-2.40%) | Price Action: 03 Dec 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Abbott is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹28460.62 serves as the nearest technical reference point.
Historical Returns: 3-month: -1.75% | 6-month: +5.23% | 1-year: +27.21%
Abbott Share Price Target For 2025
The line chart displays the monthly closing prices of Abbott with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Abbott shares in 2025, see the table below.
Abbott Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 35899.43 (+25.28%) | Fibonacci Extension Level 82.00% |
| 2025 Target 2 | 34938.12 (+21.92%) | Fibonacci Extension Level 150.00% |
| 2025 Target 1 | 34388.78 (+20.00%) | Fibonacci Extension Level 64.90% |
| Current Price | 28655.35 | Abbott's share price as of 20 Dec 2024 |
| Stop Loss 1 | 27305.6 (-4.72%) | Price Action: Apr 2024 High |
| Stop Loss 2 | 26912.1 (-6.09%) | Price Action: Nov 2024 Low |
| Stop Loss 3 | 26103.88 (-8.91%) | Fibonacci Retracement Level 50.00% |
Long-Term Technical Outlook
52-Week Range Analysis: Abbott is currently trading near its 52-week high of ₹30521, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +27.21% | 3-year: +52.22% | 5-year: +130.32%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Abbott Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹28,655.35 | ||
| 2024 | ₹29,235.86 | +2.03% | ₹29,674.40 |
| 2025 | ₹31,725.18 | +8.51% | ₹32,427.47 |
| 2026 | ₹32,337.75 | +1.93% | ₹33,574.96 |
| 2027 | ₹35,395.06 | +9.45% | ₹36,432.05 |
| 2028 | ₹38,806.35 | +9.64% | ₹39,388.45 |
| 2029 | ₹40,389.51 | +4.08% | ₹41,099.39 |
| 2030 | ₹42,970.49 | +6.39% | ₹43,990.03 |
| 2031 | ₹43,041.40 | +0.17% | ₹45,003.33 |
| 2032 | ₹46,383.25 | +7.76% | ₹47,860.43 |
| 2033 | ₹50,149.28 | +8.12% | ₹50,901.52 |
| 2034 | ₹51,543.16 | +2.78% | ₹52,661.94 |
| 2035 | ₹54,215.80 | +5.19% | ₹55,552.58 |
| 2036 | ₹53,745.04 | -0.87% | ₹56,431.71 |
| 2037 | ₹57,371.44 | +6.75% | ₹59,288.81 |
| 2038 | ₹61,492.21 | +7.18% | ₹62,414.59 |
| 2039 | ₹63,554.09 | +3.35% | ₹64,507.40 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Abbott Brief Company Overview
Abbott India Limited: A Leader in Pharmaceuticals Established in 1910, Abbott India Limited is a leading pharmaceutical company in India. With a diverse product portfolio, Abbott India caters to a wide range of therapeutic areas, including women's health,...
gastroenterology, metabolism, and vaccines. Key Products and Services: Pharmaceutical products for various therapeutic areas Multispecialty products for insomnia, vitamin D, pre-term labor, and pain management Anti-infectives, cardio-diabetic, hormones, respiratory, hepatic, consumer care, and gastro products Reputation and Commitment: Abbott India has earned a strong reputation in the industry for its commitment to quality and innovation. The company is dedicated to providing affordable healthcare solutions to its customers.Abbott Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 57,849.83 Crore | Market valuation of Abbott's shares. |
| Revenue (TTM) | 6,066.04 Crore | Total revenue generated by Abbott over the past twelve months. |
| Net Income (TTM) | +12,846,600,192.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +25.81% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +21.17% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+9.30% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+14.60% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
1.71 | Company's total debt divided by total shareholder equity. |
| Total Debt | 60.5 Crore | Sum of Abbott's current & long-term financial obligations. |
| Total Cash | 1,105.7 Crore | Total amount of liquid funds available to Abbott. |
| Beta | 0.01 | Beta is less than 1 indicating that the Abbott's price is less volatile than the market. |
Is Abbott A Good Buy For Long Term?
Abbott, with a market cap of ₹57,849.83 crore, shows strong financial health. Its ₹1,284.66 crore net profit in the last 12 months, representing a 21.17% profit margin, and a positive year-on-year earnings growth of 14.6%, are encouraging. While recent quarterly revenue growth slowed to 9.3%, long-term returns are impressive (78.57% over three years, 278.09% over five). Considering its healthy cash balance (₹1,105.7 crore) and low debt (₹60.5 crore), Abbott presents a good buy for long-term investors.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
